Allurion Gains FDA Approval for Elipse Gastric Balloon Weight-Loss System
Allurion received U.S. FDA approval on February 23 for its swallowable Elipse gastric balloon weight-loss system, greenlighting U.S. commercial launch. The clearance underpins the company’s plan to initiate product shipments in Q2 2026 and target an obesity device market projected to exceed $1.5 billion annually.
1. FDA Approval Milestone
Allurion achieved U.S. FDA clearance on February 23, 2026, for its Elipse swallowable gastric balloon system, marking the first endoscopy-free weight-loss device approved in the country. The device is ingested in capsule form and inflated once in the stomach to facilitate non-surgical weight reduction.
2. Commercialization and Market Outlook
Following approval, Allurion plans to commence U.S. commercial shipments in Q2 2026, initially targeting leading bariatric clinics and independent weight-loss centers. Industry estimates value the U.S. non-surgical obesity device market at over $1.5 billion annually, positioning Allurion for significant revenue growth as adoption expands.